The Nephrotic Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nephrotic Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Nephrotic Syndrome by ten companies/universities/institutes. The top development phase for Nephrotic Syndrome is phase i with four drugs in that stage. The Nephrotic Syndrome pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Nephrotic Syndrome pipeline products market are: Chugai Pharmaceutical, Asahi Kasei Pharma and F. Hoffmann-La Roche.
The key targets in the Nephrotic Syndrome pipeline products market include Glucocorticoid Receptor, Inosine Monophosphate Dehydrogenase, and Enteropeptidase.
The key mechanisms of action in the Nephrotic Syndrome pipeline product include Glucocorticoid Receptor Agonist with one drug in Phase I. The Nephrotic Syndrome pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Nephrotic Syndrome pipeline products market including Small Molecule, and Gene Therapy.
Nephrotic Syndrome overview
Nephrotic syndrome is a kidney disorder that causes the body to excrete too much protein in the urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine, and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, and certain medications including non-steroidal anti-inflammatory drugs and antibiotics.
For a complete picture of Nephrotic Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
